Neuronetics Inc (STIM) Insider Sells $53,543.05 in Stock

Neuronetics Inc (NASDAQ:STIM) insider Daniel Guthrie sold 3,685 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $14.53, for a total transaction of $53,543.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ STIM traded down $0.54 during trading hours on Thursday, reaching $14.04. 90,730 shares of the company’s stock traded hands, compared to its average volume of 110,649. Neuronetics Inc has a 52-week low of $13.26 and a 52-week high of $39.39. The stock has a market cap of $273.34 million and a P/E ratio of -5.22. The company has a debt-to-equity ratio of 0.52, a current ratio of 8.94 and a quick ratio of 8.74.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.05). Neuronetics had a negative net margin of 47.21% and a negative return on equity of 1,385.60%. The business had revenue of $12.73 million for the quarter, compared to analysts’ expectations of $12.72 million. Research analysts expect that Neuronetics Inc will post -1.64 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc purchased a new position in Neuronetics during the 3rd quarter valued at about $31,000. Advisor Group Inc. purchased a new position in Neuronetics during the 4th quarter valued at about $27,000. Citigroup Inc. lifted its position in Neuronetics by 166.0% during the 1st quarter. Citigroup Inc. now owns 3,783 shares of the company’s stock valued at $58,000 after acquiring an additional 2,361 shares during the period. BNP Paribas Arbitrage SA purchased a new position in Neuronetics during the 1st quarter valued at about $41,000. Finally, Frontier Capital Management Co. LLC lifted its position in Neuronetics by 4.6% during the 4th quarter. Frontier Capital Management Co. LLC now owns 70,821 shares of the company’s stock valued at $1,370,000 after acquiring an additional 3,128 shares during the period. 72.57% of the stock is owned by institutional investors.

Several equities research analysts have recently commented on the stock. Zacks Investment Research raised shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $25.00 target price on shares of Neuronetics in a research report on Wednesday, March 6th. Finally, Piper Jaffray Companies dropped their target price on shares of Neuronetics from $35.00 to $28.00 and set an “overweight” rating for the company in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $31.60.

ILLEGAL ACTIVITY NOTICE: “Neuronetics Inc (STIM) Insider Sells $53,543.05 in Stock” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2019/05/23/neuronetics-inc-stim-insider-sells-53543-05-in-stock.html.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Read More: Beige Book

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.